LearnGlossaryMarketStocksSuperinvestorsSign in

NEO

NeoGenomics, Inc.

Healthcare · $497M market cap

Verdict

We can't put a fair value on NEO right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

3 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth23.6% a year✓
Equity per share growth15.4% a year✓
Sales growth21.2% a year✓
Free cash flow growth—?
Return on invested capital-5.7%✗

Follow NEO

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds NEO. In Q2 2026, 1 trimmed. Who we track

Howard Marks

Oaktree Capital Management · as of Q2 2026

$979.7M

1,045,000 shares

Moves in Q2 2026

Trimmed: Howard Marks

Insider activity

Since Sep 1, 2026: no open-market purchases and 1 other filing (stock awards, tax withholding and similar). Why purchases matter

Other filings

Olivo Alicia C

EVP, GC & Business Development · 2026-09-01

Tax withholding

2,692 shares

About NeoGenomics, Inc.

NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists…

Medical - Diagnostics & Research

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works